Abbisko reported FY 2025 revenue of RMB 612.1 million (+21%) and profit for the year attributable to ordinary equity holders of the parent of RMB 55.2 million (+95%), with basic and diluted EPS of RMB 0.09. R&D expenses were RMB 508.4 million (+13%) and administrative expenses were RMB 75.8 million. Cash and bank balances (including time deposits over three months and cash and cash equivalents) totaled RMB 2.0 billion as at Dec. 31, 2025 (+3%). The company said FY 2025 revenue reflected licensing revenue received from Merck, and noted pimicotinib (ABSK021) received China NMPA approval for TGCT in December 2025, while the US FDA accepted its NDA in January 2026; Merck’s global commercialization option exercise fee of USD 85 million was received in May 2025, bringing total payments received to USD 155 million. Abbisko also disclosed management changes effective March 2, 2026, including the resignation of joint company secretaries Dr. Yu Hongping and Ms. Chan Yin Wah and the appointment of Ms. Zhang Hanxi and Ms. Lin Sio Ngo, with Ms. Lin also becoming authorized representative and process agent.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260302-12036830), on March 02, 2026, and is solely responsible for the information contained therein.